What, what do they need really, I suppose, is the question.

Well, shall I start with that one? I mean, I think it's fair to, to say everybody's talking about it.

There's a lot of talk, probably not as much action as we'd like to think.

And, um, obviously, what we're gonna mainly talk about is that sort of world beyond the actual drug, so the, the market that's, say, opening up around, um, the treatment of GLP-1s.

And I always think of clients, when they enter any new space really, they fall into one of two s- camps.

They're either the sort of the mavericks, you know.

They see this opportunity, they see th- this vision, and they're just gonna go for it no matter what.

My thoughts.